Lv6
1720 积分 2023-05-11 加入
Breakthrough therapy designations in China and the United States
2个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
7个月前
已完结
Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4; a mini review
7个月前
已完结
LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial
7个月前
已完结
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration
8个月前
已完结
Screening and Functional Analyses of Nilaparvata lugens Salivary Proteome
8个月前
已完结
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial
8个月前
已完结
Mapping the patent landscape of TROP2-targeted biologics through deep learning
9个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
10个月前
已完结
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab
10个月前
已完结
皖公网安备34019202002308
